{"id":"vaqta-injectable-product","safety":{"commonSideEffects":[{"rate":"20-50","effect":"Injection site soreness or swelling"},{"rate":"5-15","effect":"Headache"},{"rate":"5-10","effect":"Fatigue"},{"rate":"1-5","effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL2094006","moleculeType":"Small molecule","molecularWeight":"702.93"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Vaqta contains inactivated (killed) hepatitis A virus antigen that triggers both humoral and cellular immune responses. Upon vaccination, the body produces specific antibodies (primarily IgG) against hepatitis A virus surface antigens, providing long-term protection against infection. The vaccine typically confers immunity after the primary series and booster dose.","oneSentence":"Vaqta is an inactivated hepatitis A vaccine that stimulates the immune system to produce antibodies against hepatitis A virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:39:22.204Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of hepatitis A infection in adults and children"}]},"trialDetails":[{"nctId":"NCT02868970","phase":"PHASE4","title":"Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfaction","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2017-02-15","conditions":"Healthy","enrollment":2404},{"nctId":"NCT06209398","phase":"PHASE4","title":"Immunogenicity of the Inactivated EV71 Vaccine Combined With Hepatitis B and Group A Meningococcal Vaccine","status":"UNKNOWN","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2018-05-24","conditions":"Hand, Foot and Mouth Disease","enrollment":510},{"nctId":"NCT03180359","phase":"NA","title":"Vaccines Immunogenicity in Renal, Hepatic, Cardiac or Pulmonary Transplanted Children","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2016-01-01","conditions":"Transplantation","enrollment":55},{"nctId":"NCT03855176","phase":"PHASE4","title":"Effectiveness of Booster With 1 or 2 Doses of HAV Vaccine Among HIV-infected Patients","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2017-09-12","conditions":"Hepatitis A, Human Immunodeficiency Virus, Vaccine Response Impaired","enrollment":153},{"nctId":"NCT03039790","phase":"PHASE2","title":"Long-Term Immunogenicity of the Norovirus GI.1/GII.4 Bivalent Virus-like Particle (VLP) Vaccine (NoV Vaccine) in Adults","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-02-21","conditions":"Healthy Volunteers, Norovirus","enrollment":528},{"nctId":"NCT02376036","phase":"PHASE1","title":"Phase 1 Study of MGD010 in Healthy Subjects","status":"COMPLETED","sponsor":"MacroGenics","startDate":"2015-02","conditions":"Healthy Subjects","enrollment":73},{"nctId":"NCT02109354","phase":"PHASE1","title":"Safety of and Immune Response to Vaccination With 2 Experimental HIV Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"HIV Vaccine Trials Network","startDate":"2013-06-18","conditions":"HIV Infection","enrollment":202},{"nctId":"NCT00414050","phase":"PHASE3","title":"A Study of 2 Doses of a Hepatitis B Vaccine (V232 RECOMBIVAX HB) in Healthy Infants (V232-057)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-10-06","conditions":"Hepatitis B","enrollment":1718},{"nctId":"NCT02296463","phase":"PHASE1","title":"A Phase I Randomized, Observer-Blinded, Dose-Ranging Study in Healthy Subjects 24 to <72 Months of Age","status":"COMPLETED","sponsor":"Novavax","startDate":"2014-11","conditions":"Respiratory Synctial Virus","enrollment":32},{"nctId":"NCT00244374","phase":"NA","title":"A Randomized Trial of Vaccine Adherence in Young Injection Drug Users","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2004-08","conditions":"Medication Adherence, Substance Abuse, Intravenous, Risk Behavior","enrollment":546}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Vaqta Injectable Product","genericName":"Vaqta Injectable Product","companyName":"National Taiwan University Hospital","companyId":"national-taiwan-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vaqta Injectable Product is a small molecule vaccine that is administered via a 0.5mL injection. It is used to prevent Hepatitis A, and has also been studied for its potential to prevent Respiratory Syncytial Virus, Transplantation complications, Hand, Foot and Mouth Disease, and Human Immunodeficiency Virus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}